Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
Pancreas|December 20, 2019
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine TumorsJames R Howe, Nipun B Merchant, Claudius Conrad, et al.
Cancer|August 28, 2024
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomesAndrew J Bishop, Devarati Mitra, Ahsan Farooqi, et al.
The Lancet. Oncology|November 7, 2022
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trialB Ashleigh Guadagnolo, Roland L Bassett, Devarati Mitra, et al.
International Journal of Cancer|February 7, 2022
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma centerElise F Nassif, Brandon Cope, Raymond Traweek, et al.
Frontiers in Immunology|May 15, 2025
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experienceMadeline B Torres, Cheuk Hong Leung, Marianne Zoghbi, et al.
Molecular Carcinogenesis|November 27, 2024
Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1Katarzyna Tomczak, Manishkumar S Patel, Angela D Bhalla, et al.
Annals of Surgical Oncology|August 24, 2023
Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal MalignancyNolan M Winicki, Shannon N Radomski, Isabella S Florissi, et al.
JAMA Network Open|February 28, 2024
Serum Tumor Markers and Outcomes in Patients With Appendiceal AdenocarcinomaAbdelrahman Yousef, Mahmoud Yousef, Mohammad A Zeineddine, et al.
Acta Neuropathologica|July 20, 2021
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated stateVeena Kochat, Ayush T Raman, Sharon M Landers, et al.
Cancer Discovery|July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal MesotheliomaKanwal Raghav, Suyu Liu, Michael J Overman, et al.
Pageof 16